Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
Recruiting · NCT04798898 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Aarhus
View the official record on ClinicalTrials.gov →Interventions studied
RFA (radiofrequency ablation)
What this trial is about
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
Who can take part
Age range
18 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with colorectal liver metastases planned for resection
- At least one tumor size \>=3cm
- Performance status 0-1
Exclusion criteria
- Liver cirrhosis
- Extrahepatic metastases that can not be addressed curatively
- Other malignant diseases within 5 years prior to diagnosis
- Prior RFA treatment
Where it is running
1 location listed.
- Aarhus University Hospital, Department of Surgery - Aarhus, Denmark